Medicine guide

Emblaveo

·

  • Prescription status not stated
  • Antibiotics, antivirals and antifungals taken into the body
Active substance
Aztreonam;avibactam
Made by
Pfizer Europe MA EEIG

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Emblaveo is indicated for the treatment of the following infections in adult patients (see sections 4.4 and 5.1):• Complicated intra-abdominal infection (cIAI)• Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • Complicated urinary tract infection (cUTI), including pyelonephritisEmblaveo is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options (see sections 4.2, 4.4, and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

SpainNo exact match for this strength and form

Details

Made byPfizer Europe MA EEIG
Active substanceAztreonam;avibactam
Used inAntibiotics, antivirals and antifungals taken into the body
ClassificationJ01DF51 · Antibiotics, antivirals and antifungals taken into the body
Authorised on2024-04-22
Last updated by the regulator2026-02-23
EMA product numberEMEA/H/C/006113

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).